Hydreight Technologies Inc

Hydreight Technologies Inc. sees Q3 2025 revenue double, driving growth in digital health segments like GLP‑1 therapies and at‑home testing, boosting its TSX Venture stock and parent Victory Square’s portfolio.

Hydreight Technologies invests in Insu Therapeutics’ buccal delivery platform, aiming to expedite peptide‑therapy distribution and boost its digital health network.

Hydreight Technologies’ $300k stake in Insu Therapeutics boosts its digital health platform, tapping innovative peptide delivery tech for future U.S. pharmacy and telehealth expansion.

Hydreight Technologies Inc. shares hit a 63% drop, now trading at $3.52 CAD—analyzing the volatility, market cap, and future prospects for TSX investors.

Hydreight Technologies Inc. raises $15 M in an oversubscribed life‑style deal, driving a 350‑P/E, 16‑P/B valuation that signals high growth expectations and strong investor interest in its Canadian healthcare strategy.

Hydreight Technologies closes a $10 M private placement to boost its digital health platform and pharmaceutical line, driving growth across North America.

Hydreight Technologies Inc. is a Canadian capital pool company poised to shape the future of technology and investment, having been invited to present at the Maxim Group’s 2025 Virtual Tech Conference.

Hydreight Technologies Inc.’s stock has experienced significant volatility on the TSX Venture Exchange, with a 52-week high of 2.99 CAD and a 52-week low of 0.2 CAD, leaving investors questioning its potential for success.